RxDoctor Payments Data

Charles Villoch, MD

Cardiovascular Disease · Bristol, TNNPI 1437251899

Payments from drug & device makers

$25,588in general payments, 2019–2025

Across 510 payments — averaging $50.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15K
  • Irhythm Technologies, Inc.$1K
  • Johnson & Johnson$1K
  • Abbott$1K
  • AstraZeneca$1K
  • Novartis$1K
  • plus $4K from 16 others

What the payments were for

  • Speaking & faculty fees$14,25056%
  • Travel & lodging$1,0004%
  • Food & beverage$10,20240%
  • Education$1351%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,588 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$111,628
Medicare patients
656
Services billed
2,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban348$259,512
EntrestoSacubitril/Valsartan212$193,835
XareltoRivaroxaban88$88,342
Repatha SureclickEvolocumab32$30,482
JardianceEmpagliflozin25$27,394
BrilintaTicagrelor34$24,265
FarxigaDapagliflozin Propanediol18$18,515
Dabigatran EtexilateDabigatran Etexilate Mesylate29$5,380
Ranolazine ErRanolazine60$3,595
Metoprolol Succinate239$2,180
Atorvastatin Calcium132$1,098
Furosemide186$1,056
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$1,043
Nitroglycerin48$1,003
Potassium Chloride53$965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$447$259,512348 claims
NovartisEntresto$1,097$193,835212 claims
Johnson & JohnsonXarelto$1,181$88,34288 claims
AstraZenecaBrilinta, Farxiga$1,144$42,78052 claims
Boehringer IngelheimJardiance$594$27,39425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →